Literature DB >> 10098671

Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives.

M Roe1, A Folkes, P Ashworth, J Brumwell, L Chima, S Hunjan, I Pretswell, W Dangerfield, H Ryder, P Charlton.   

Abstract

We have synthesised and evaluated a series of anthranilamide based modulators of P-glycoprotein. These studies have identified XR9576(2), a potent inhibitor of P-glycoprotein in vitro and in vivo. The general synthesis and the SAR of these compounds are described.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10098671     DOI: 10.1016/s0960-894x(99)00030-x

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  38 in total

Review 1.  Functional expression and localization of P-glycoprotein in the central nervous system: relevance to the pathogenesis and treatment of neurological disorders.

Authors:  Gloria Lee; Reina Bendayan
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

2.  The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2).

Authors:  Pavitra Kannan; Sanjay Telu; Suneet Shukla; Suresh V Ambudkar; Victor W Pike; Christer Halldin; Michael M Gottesman; Robert B Innis; Matthew D Hall
Journal:  ACS Chem Neurosci       Date:  2010-10-21       Impact factor: 4.418

Review 3.  Therapeutic strategies to improve drug delivery across the blood-brain barrier.

Authors:  Tej D Azad; James Pan; Ian D Connolly; Austin Remington; Christy M Wilson; Gerald A Grant
Journal:  Neurosurg Focus       Date:  2015-03       Impact factor: 4.047

4.  Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice.

Authors:  Martina Hubensack; Christine Müller; Peter Höcherl; Stephan Fellner; Thilo Spruss; Günther Bernhardt; Armin Buschauer
Journal:  J Cancer Res Clin Oncol       Date:  2007-10-12       Impact factor: 4.553

Review 5.  Structure-activity relationships of tariquidar analogs as multidrug resistance modulators.

Authors:  Ilza K Pajeva; Michael Wiese
Journal:  AAPS J       Date:  2009-06-06       Impact factor: 4.009

Review 6.  Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies.

Authors:  Chung-Pu Wu; Anna Maria Calcagno; Suresh V Ambudkar
Journal:  Curr Mol Pharmacol       Date:  2008-06       Impact factor: 3.339

7.  Cryo-EM structures reveal distinct mechanisms of inhibition of the human multidrug transporter ABCB1.

Authors:  Kamil Nosol; Ksenija Romane; Rossitza N Irobalieva; Amer Alam; Julia Kowal; Naoya Fujita; Kaspar P Locher
Journal:  Proc Natl Acad Sci U S A       Date:  2020-10-05       Impact factor: 11.205

Review 8.  Nuclear export of proteins and drug resistance in cancer.

Authors:  Joel G Turner; Jana Dawson; Daniel M Sullivan
Journal:  Biochem Pharmacol       Date:  2011-12-20       Impact factor: 5.858

9.  Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes.

Authors:  Niravkumar R Patel; Alok Rathi; Dmitriy Mongayt; Vladimir P Torchilin
Journal:  Int J Pharm       Date:  2011-06-15       Impact factor: 5.875

10.  Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform.

Authors:  Yilin Zhang; Shravan Kumar Sriraman; Hilary A Kenny; Ed Luther; Vladimir Torchilin; Ernst Lengyel
Journal:  Mol Cancer Ther       Date:  2016-07-27       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.